Skip to content
OpenCapital
Get started

Veradermics MANE Q1 2026 earnings

Reported May 12, 2026 · Before market open

Diluted EPS-$1.32Miss by $0.76
EPS estimate-$0.56

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.66

Financials

Q1 2026

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total equity$390.6M+744%
Total assets$397.4M—

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Versus estimates

Diluted EPS

Q1 2026-$1.32Miss by $0.76
Q4 2024-$1.06Beat by $0.75Q4 2025-$1.63Beat by $0.19

Ask the moment Veradermics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Veradermics report Q1 2026 earnings?
Veradermics (MANE) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Veradermics 's Q1 2026 revenue and EPS?
Veradermics reported diluted EPS of $-1.32 for Q1 2026.
Did Veradermics beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.56 by $0.76.
Where can I find Veradermics 's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001827635-26-000016) and the 10-Q periodic report (0001827635-26-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.